BridgeBio Pharma, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 2CL.F | IONS | ALNY | BMRN | ROIV | GPCR | |
|---|---|---|---|---|---|---|
| Market cap | 13.27B | 6.67B | 21.57B | 11.07B | 27.61B | 1.45B |
| P/E (TTM) | — | — | 8.1 | — | — | — |
| Forward P/E | -19.0 | -35.0 | 14.4 | 9.0 | -27.5 | -9.6 |
| Price/book | -5.8 | 15.1 | 6.0 | 1.8 | 6.5 | 1.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +21.56% | −45.82% | −63.43% | +10.20% | +85.85% | −39.17% |
| Today | +3.49% | −0.67% | +0.74% | +2.64% | +6.08% | +0.05% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All 2CL.F news ›Analyzing Arcus Biosciences (NYSE:RCUS) & BridgeBio Pharma (NASDAQ:BBIO)
Posted by Kim Johansen on Nov 3rd, 2026 Arcus Biosciences (NYSE:RCUS – Get Free Report) and BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two…
Should You Invest $1,000 in BridgeBio Pharma Right Now?
BridgeBio Pharma (BBIO +5.97%) is a biotech on the verge of a breakout. The company focuses on rare genetic diseases. It has only two approved therapies right now: Attruby and Nulibry. Attruby is the company's main earner right now. The…
BridgeBio Pharma: BlackRock reports 5.1% stake
Palantir Reports Q3 2026 U.S. Comm Revenue Growth of 148% Y/Y and Revenue Growth of 96% Y/Y; Raises FY 2026 Revenue Guidance to 91% Y/Y Growth and U.S. Comm Revenue Guidance to 143% Y/Y, Crushing Consensus Expectations Aehr Test Systems…
BridgeBio Pharma Q3 2026 revenue rises to $353M
SEGG Media Reports More Than 1,500% Year-Over-Year Revenue Growth in Second Quarter, Driven by Veloce uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the…
Q3 revenue reaches $353M as BridgeBio Pharma (BBIO) narrows its net loss.
uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease SEGG Media Reports More Than 1,500% Year-Over-Year Revenue Growth in Second…
What BridgeBio Pharma (BBIO) Said on Its Q3 Earnings Call
Posted by Mitch Edgeman on Nov 1st, 2026 BridgeBio Pharma (NASDAQ:BBIO) reported third-quarter revenue growth driven by sales of ATTR cardiomyopathy treatment Attruby and a one-time milestone tied to European partner Bayer’s…
More from 1 other outlet
Morgan Stanley Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price
Posted by Defense World Staff on Oct 31st, 2026 BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price lifted by Morgan Stanley from $87.00 to $88.00 in a research note issued to investors on Friday morning,Benzinga reports. The…
BridgeBio Pharma (NASDAQ:BBIO) Stock Crosses Above Fifty Day Moving Average – Should You Sell?
Posted by Michael Walen on Oct 31st, 2026 BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report)’s share price crossed above its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $70.70 and…
BridgeBio Pharma GAAP EPS of -$0.42 beats by $0.17, revenue of $353.17M beats by $57.42M
BridgeBio Pharma beat Q3 EPS and revenue estimates as sales surged 192.6% year over year. - BridgeBio Pharma press release (BBIO): Q3 GAAP EPS of -$0.42 beats by $0.17. - Revenue of $353.17M (+192.6% Y/Y) beats by $57.42M.
BridgeBio Pharma: Q3 Earnings Snapshot
PALO ALTO, Calif. (AP) — PALO ALTO, Calif. (AP) — BridgeBio Pharma Inc. (BBIO) on Thursday reported a loss of $56.7 million in its third quarter. The Palo Alto, The Palo Alto, California-based company said it had a loss of 42 cents per…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com12
- markets.businessinsider.com4
- gurufocus.com3
- seekingalpha.com2
- manilatimes.net1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 29 articles, not a forecast.